ClinConnect ClinConnect Logo
Search / Trial NCT06036823

5 Versus 10 Units of Insulin in Hyperkalemia Management

Launched by OMAN MEDICAL SPECIALITY BOARD · Sep 11, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Insulin Hyperkalemia Hypoglycmiea Anti Hyperkalemia Electrolytes Abnormalities

ClinConnect Summary

This clinical trial is studying how effective two different doses of insulin are in treating hyperkalemia, which is a condition where there is too much potassium in the blood. The researchers want to find out whether giving patients 5 units or 10 units of intravenous insulin will better lower potassium levels over a period of 2 hours.

To be eligible for this study, participants need to be adults aged 18 or older who have high potassium levels of 5.5 mEq/L or more. However, certain conditions like heart failure, very high or low blood sugar levels, pregnancy, and other serious health issues may prevent someone from participating. If you join the study, you can expect to receive either the 5-unit or 10-unit dose of insulin and have your potassium levels checked after two hours to see how well the treatment worked. This trial is important because it could help doctors decide the best way to manage hyperkalemia and improve patient care.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Hyperkalemia patients with lab potassium levels equal to or more than 5.5 mEq/L (≥ 5.5 mEq/L)+.
  • Adult: age 18 years or more.
  • Agreed to participate in the study.
  • If an investigator decides to start anti-hyperkalemia medications based on the VBG/ABG patient can be enrolled but if the main laboratory value is less than 5.5 mEq/L patients will be excluded
  • Exclusion Criteria:
  • Cardiac arrest
  • Hyperglycemia with random blood sugar 20 mmol/L (13) or with acute diabetic complications like Diabetic Ketoacidosis / Hyperosmolar Hyperglycemic State.
  • Hypoglycemia with random blood sugar (RBS) ≤ 3.89 mmol/l in Diabetic patients and less than 3 mmol/l in non-diabetic patients.
  • Allergies for any medication in the protocol.
  • Pregnancy.
  • Hemolyzed potassium level as reported by the main lab.
  • Hemolysis, Tumor lysis syndrome, or Rhabdomyolysis due to the ongoing release of potassium.
  • Acidosis with a pH less than 7.1 will require Sodium bicarbonate (NaHO3).
  • A patient who will need urgent Furosemide (Lasix), and or dialysis during the study period of 2 hours.
  • Refused to participate.

About Oman Medical Speciality Board

The Oman Medical Specialty Board (OMSB) is a leading regulatory and educational authority dedicated to advancing medical education and healthcare standards in Oman. Established to enhance the quality of medical training and practice, OMSB plays a pivotal role in overseeing clinical trials, ensuring they adhere to rigorous ethical and scientific standards. By fostering collaboration between healthcare professionals, researchers, and institutions, OMSB aims to promote evidence-based medicine and drive innovation in clinical practices, ultimately improving patient outcomes and healthcare delivery in the region.

Locations

Seeb, Muscat, Oman

Patients applied

0 patients applied

Trial Officials

Suad Al-Abri

Principal Investigator

Sultan Qaboos University hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported